EA202091464A1 - Композиции для лечения неалкогольной жировой болезни печени и неалкогольного стеатогепатита - Google Patents
Композиции для лечения неалкогольной жировой болезни печени и неалкогольного стеатогепатитаInfo
- Publication number
- EA202091464A1 EA202091464A1 EA202091464A EA202091464A EA202091464A1 EA 202091464 A1 EA202091464 A1 EA 202091464A1 EA 202091464 A EA202091464 A EA 202091464A EA 202091464 A EA202091464 A EA 202091464A EA 202091464 A1 EA202091464 A1 EA 202091464A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- alcoholic
- treatment
- liver disease
- compositions
- fat liver
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862630361P | 2018-02-14 | 2018-02-14 | |
| PCT/US2019/017964 WO2019161025A1 (en) | 2018-02-14 | 2019-02-14 | Compositions for the treatment of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA202091464A1 true EA202091464A1 (ru) | 2020-12-07 |
Family
ID=67620042
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA202091464A EA202091464A1 (ru) | 2018-02-14 | 2019-02-14 | Композиции для лечения неалкогольной жировой болезни печени и неалкогольного стеатогепатита |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US20210059993A1 (https=) |
| EP (3) | EP4623929A3 (https=) |
| JP (3) | JP2021513552A (https=) |
| KR (2) | KR20200121308A (https=) |
| CN (2) | CN118453597A (https=) |
| AU (2) | AU2019222736B2 (https=) |
| BR (1) | BR112020016613A2 (https=) |
| CA (1) | CA3088177A1 (https=) |
| EA (1) | EA202091464A1 (https=) |
| WO (1) | WO2019161025A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113646327A (zh) * | 2019-03-29 | 2021-11-12 | 综合医院公司 | 用于治疗肝脏疾病的ghrh或其类似物 |
| WO2022059946A1 (ko) * | 2020-09-18 | 2022-03-24 | 서울대학교 산학협력단 | 비알코올성 지방간염 및 간 섬유화의 치료를 위한 약학적 조성물 |
| KR20220132312A (ko) | 2021-03-23 | 2022-09-30 | 한국과학기술원 | 간세포의 IFN-γR1 매개 지질생성작용 억제를 통한 비알코올성 지방간 질환의 치료 방법 |
| KR20250107210A (ko) * | 2022-11-03 | 2025-07-11 | 루모스 파마, 인크. | 이부타모렌의 압축형 경구 제형 |
| WO2025193784A1 (en) * | 2024-03-12 | 2025-09-18 | Lumos Pharma, Inc. | Pharmaceutical formulations for maintaining lean muscle mass during weight loss treatment |
| WO2025217521A1 (en) * | 2024-04-12 | 2025-10-16 | Jnana Therapeutics Inc. | Treating chronic kidney disease with a combination of a slc6a19 inhibitor and a glp-1 agonist |
| CN119405782A (zh) * | 2025-01-06 | 2025-02-11 | 山东大学 | 胰岛素样生长因子结合蛋白-1在制备治疗非酒精性脂肪性肝病药物中的应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL145106A0 (en) * | 2000-08-30 | 2002-06-30 | Pfizer Prod Inc | Intermittent administration of a geowth hormone secretagogue |
| US20070123470A1 (en) * | 2003-10-24 | 2007-05-31 | Wladimir Hogenhuis | Enhancement of growth hormone levels with a dipeptidyl peptidase IV inhibitor and a growth hormone secretagogue |
| JP2007532495A (ja) * | 2004-04-07 | 2007-11-15 | ガストロテック・ファルマ・アクティーゼルスカブ | グレリン欠乏を治療するための分泌促進薬の使用 |
| PE20100156A1 (es) * | 2008-06-03 | 2010-02-23 | Boehringer Ingelheim Int | Tratamiento de nafld |
| US20090312302A1 (en) * | 2008-06-17 | 2009-12-17 | Ironwood Pharmaceuticals, Inc. | Compositions and methods for treating nonalcoholic fatty liver disease-associated disorders |
| BR112017004708A2 (pt) * | 2014-09-12 | 2017-12-05 | Tobira Therapeutics Inc | terapia de combinação de cenicriviroc para o tratamento de fibrose |
| US20180360846A1 (en) * | 2015-09-16 | 2018-12-20 | Tobira Therapeutics, Inc. | Cenicriviroc combination therapy for the treatment of fibrosis |
| WO2019008554A1 (en) * | 2017-07-06 | 2019-01-10 | Conte Anthony | METHOD FOR ORAL TREATMENT AND PREVENTION OF CARDIOVASCULAR DISEASE |
-
2019
- 2019-02-14 KR KR1020207023368A patent/KR20200121308A/ko not_active Ceased
- 2019-02-14 EP EP25195764.3A patent/EP4623929A3/en active Pending
- 2019-02-14 CN CN202410528969.XA patent/CN118453597A/zh active Pending
- 2019-02-14 EP EP19755124.5A patent/EP3781158A4/en not_active Ceased
- 2019-02-14 EP EP24205490.6A patent/EP4467158A3/en not_active Withdrawn
- 2019-02-14 CA CA3088177A patent/CA3088177A1/en active Pending
- 2019-02-14 BR BR112020016613-8A patent/BR112020016613A2/pt unknown
- 2019-02-14 KR KR1020247002905A patent/KR20240015742A/ko not_active Ceased
- 2019-02-14 AU AU2019222736A patent/AU2019222736B2/en active Active
- 2019-02-14 EA EA202091464A patent/EA202091464A1/ru unknown
- 2019-02-14 CN CN201980013533.4A patent/CN111727041A/zh active Pending
- 2019-02-14 WO PCT/US2019/017964 patent/WO2019161025A1/en not_active Ceased
- 2019-02-14 US US16/961,564 patent/US20210059993A1/en not_active Abandoned
- 2019-02-14 JP JP2020543742A patent/JP2021513552A/ja not_active Withdrawn
-
2023
- 2023-08-09 US US18/231,977 patent/US20230381158A1/en not_active Abandoned
- 2023-12-27 JP JP2023221157A patent/JP2024028337A/ja active Pending
-
2024
- 2024-08-07 AU AU2024205599A patent/AU2024205599A1/en active Pending
-
2025
- 2025-05-27 US US19/219,112 patent/US20250281470A1/en active Pending
- 2025-08-04 JP JP2025129927A patent/JP2025179056A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2025179056A (ja) | 2025-12-09 |
| US20250281470A1 (en) | 2025-09-11 |
| EP4623929A2 (en) | 2025-10-01 |
| CA3088177A1 (en) | 2019-08-22 |
| BR112020016613A2 (pt) | 2020-12-22 |
| EP4623929A3 (en) | 2025-12-17 |
| EP3781158A1 (en) | 2021-02-24 |
| EP4467158A2 (en) | 2024-11-27 |
| AU2019222736B2 (en) | 2024-08-01 |
| WO2019161025A1 (en) | 2019-08-22 |
| JP2021513552A (ja) | 2021-05-27 |
| AU2019222736A1 (en) | 2020-07-30 |
| CN118453597A (zh) | 2024-08-09 |
| KR20200121308A (ko) | 2020-10-23 |
| US20210059993A1 (en) | 2021-03-04 |
| EP3781158A4 (en) | 2022-03-16 |
| CN111727041A (zh) | 2020-09-29 |
| KR20240015742A (ko) | 2024-02-05 |
| EP4467158A3 (en) | 2025-02-19 |
| US20230381158A1 (en) | 2023-11-30 |
| AU2024205599A1 (en) | 2024-08-22 |
| JP2024028337A (ja) | 2024-03-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA202091464A1 (ru) | Композиции для лечения неалкогольной жировой болезни печени и неалкогольного стеатогепатита | |
| EA202091290A1 (ru) | Аналоги инкретина и их применение | |
| SA521422068B1 (ar) | عوامل مساعدة لـ glp-1r واستخداماتها | |
| EA202091284A1 (ru) | Аналоги инкретина и их применение | |
| MX2018005193A (es) | Proteinas de doble funcion y composicion farmaceutica que comprende las mismas. | |
| EA200701705A1 (ru) | Антагонисты рецепторы глюкагона, получение и терапевтическое применение | |
| MX2020010547A (es) | Anticuerpo agonista del receptor de leptina para usarse en el tratamiento de una disfuncion metabolica o hipoleptinemia. | |
| JOP20210326A1 (ar) | أجسام مضادة للمستقبل 1 لببتيد إدرار الصوديوم في البول وطرق استخدامها | |
| MX376312B (es) | Uso de antagonistas del receptor ep4 para el tratamiento de cancer de higado asociado con nash | |
| MX2023014771A (es) | Conjugados peptidicos duales gip/glp-1 de accion prolongada y metodos de uso. | |
| MX2020010740A (es) | Composiciones de proteina de fusion recombinante neuregulina-1 (nrg-1) humana y metodos para su uso. | |
| MX2021008010A (es) | Composiciones y métodos para tratar las enfermedades del hígado graso no alcohólico (nafld). | |
| MX2025015078A (es) | Formulaciones de analogos peptidicos de oxintomodulina | |
| MX2022000388A (es) | Terapia de combinacion de agonista de gpr119 e inhibidores de dpp-4. | |
| MX2025000641A (es) | Composiciones y métodos para el tratamiento del trastorno metabólico y el hígado | |
| WO2020225799A3 (en) | A method of decreasing concentration of tau (τ) protein and/or phosphorylated tau (τ) protein | |
| EA202193102A1 (ru) | Инъекционные совместные составы на основе циклодекстрина, содержащие ингибиторы sglt2 и инкретиновые пептиды | |
| JOP20230150A1 (ar) | صيغ ببتيد علاجية | |
| MX2022007929A (es) | Coagonistas de triazol grapados de los receptores de glucagon y glp-1. | |
| PH12022552778A1 (en) | Glucagon analogues as long-acting glp-1/glucagon receptor agonists in the treatment of fatty liver disease and steatohepatitis | |
| EA200800181A1 (ru) | Фармацевтическая композиция glp-1 | |
| ECSP20014569A (es) | Métodos para el tratamiento de enfermedades relacionadas con tnf - alfa | |
| WO2016130901A3 (en) | Blockers of the growth hormone receptor in disease prevention and treatment | |
| EA201992630A1 (ru) | Способы лечения заболеваний глаз антагонистами aplnr и ингибиторами vegf | |
| MX2022007928A (es) | Co-agonistas de olefina engrapados de los receptores de glucagon y glp-1. |